WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low – Time to Sell?

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $4.20 and last traded at $4.26, with a volume of 2372427 shares trading hands. The stock had previously closed at $4.35.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE initiated a Phase 2a trial evaluating WVE-007, a GalNAc-siRNA targeting INHBE, in combination with tirzepatide for obesity. The company says WVE-007 may promote fat loss without muscle loss, support dosing once or twice annually, and showed roughly double the weight loss of GLP-1 treatment alone in preclinical combination studies. The trial creates a potentially important clinical catalyst, although its benefits still need to be confirmed in humans. WAVE Life Sciences Initiates Phase 2a Combination Trial of WVE-007 with Tirzepatide
• Neutral Sentiment: JPMorgan began coverage of WVE with a “neutral” rating. The initiation provides additional institutional research coverage but does not offer a bullish valuation signal. JPMorgan begins coverage of WAVE Life Sciences
• Neutral Sentiment: WAVE appointed Dr. Monika Vnuk as chief business officer. Her prior experience at Sanofi, Blackstone, and Pfizer could support partnering and corporate-development efforts, but the announcement has no immediate financial impact. WAVE Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
• Negative Sentiment: WVE reached a new 52-week low, highlighting continued investor pressure and concern about the company’s early-stage pipeline and cash-burning biotech model. The comparison with Septerna appears informational rather than a new company-specific catalyst. WAVE Life Sciences Hits New 52-Week Low

Analysts Set New Price Targets

A number of research firms have commented on WVE. Citigroup lowered their price objective on WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. New Street Research set a $13.00 target price on WAVE Life Sciences in a research report on Thursday, June 11th. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a report on Monday, August 3rd. UBS Group set a $13.00 price target on WAVE Life Sciences in a research report on Monday, August 3rd. Finally, Zacks Research downgraded WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, WAVE Life Sciences has a consensus rating of “Moderate Buy” and an average price target of $22.31.

WAVE Life Sciences Price Performance

The firm has a market capitalization of $778.35 million, a price-to-earnings ratio of -3.62 and a beta of -1.30. The firm’s 50-day simple moving average is $5.22 and its 200 day simple moving average is $6.68.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The business had revenue of $2.27 million during the quarter, compared to the consensus estimate of $7.45 million. As a group, research analysts predict that WAVE Life Sciences Ltd. will post -1.11 earnings per share for the current year.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, Director Adrian Rawcliffe sold 12,700 shares of WAVE Life Sciences stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Heidi Wagner sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. The trade was a 13.48% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 23,564 shares of company stock worth $132,476. Company insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On WAVE Life Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AlphaGrep UK Ltd bought a new stake in shares of WAVE Life Sciences during the second quarter worth $78,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of WAVE Life Sciences during the 4th quarter valued at $82,000. First Trust Advisors LP grew its position in WAVE Life Sciences by 15.7% during the 1st quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock worth $98,000 after acquiring an additional 1,830 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in WAVE Life Sciences during the 2nd quarter worth $111,000. Finally, Chicago Partners Investment Group LLC acquired a new position in WAVE Life Sciences in the 1st quarter worth about $124,000. Institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that target RNA, the biological molecule that helps translate genetic information into proteins. The company uses its oligonucleotide chemistry and delivery technologies to pursue treatments for genetically defined diseases, including conditions affecting the liver, muscles and nervous system.

WAVE’s research programs include RNA editing medicines designed to correct or modify disease-related genetic messages without permanently altering DNA.